What does ESTEVE PHARMACEUTICALS do?

ESTEVE PHARMACEUTICALS is a wholesaler in Jette. Private Limited, started on 2 January 2014, 2 establishments.

What is the address of ESTEVE PHARMACEUTICALS?

The registered office of ESTEVE PHARMACEUTICALS is located at Burgemeester Etienne Demunterl. 5 box 10, 1090 Jette.

Is ESTEVE PHARMACEUTICALS still active?

Yes. According to the CBE (2 November 2026) ESTEVE PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 2 January 2014.

Is ESTEVE PHARMACEUTICALS registered on Peppol?

Yes, ESTEVE PHARMACEUTICALS is registered on the Peppol network with ID 0208:0543727164.

What is the enterprise number of ESTEVE PHARMACEUTICALS?

The enterprise number of ESTEVE PHARMACEUTICALS is BE0543727164.

When was ESTEVE PHARMACEUTICALS founded?

ESTEVE PHARMACEUTICALS was founded on 2 January 2014.

Who are the directors of ESTEVE PHARMACEUTICALS?

According to the 2025 annual accounts, the directors of ESTEVE PHARMACEUTICALS are: Jacob Tolstrup, Ivan Hagay.

Is ESTEVE PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 January 2014; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did ESTEVE PHARMACEUTICALS make in 2025?

ESTEVE PHARMACEUTICALS recorded a loss after taxes of € 130,435 in financial year 2025.

What is the revenue of ESTEVE PHARMACEUTICALS?

In its most recent annual accounts (2025), ESTEVE PHARMACEUTICALS reported revenue of € 887,368.

How much does an employee at ESTEVE PHARMACEUTICALS earn?

The average wage cost per full-time employee at ESTEVE PHARMACEUTICALS was € 145,200 in 2022: staff costs of € 377,404 for 2.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

ESTEVE PHARMACEUTICALS (Private Limited) - Jette

Dossier ESTEVE PHARMACEUTICALS, printed on 2 November 2026 from databakkes.be/en/0543727164/esteve-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

68 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

ESTEVE PHARMACEUTICALS from Jette, company number BE0543727164, closed financial year 2025 with a result of € -130,435 after tax. For that financial year ESTEVE PHARMACEUTICALS recorded revenue of € 887,368 and equity of € 703,944. Compared with financial year 2024, the result moved from € 142,934 to € -130,435. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 16, 2026.

What it is worth Healthy

€ 703,944

▼ 16% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -130,435

▼ still € 142,934 profit in 2024

Profit after tax over the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 685,394.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 468,343

▲ € 382,465 vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 188 days on average.

Taxes

€ 2,385

▼ 87% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 6,393,656 Revenue 2022: € 6,393,656 First fiscal year in the series	€ 1,326,048 Revenue 2023: € 1,326,048 ▼ 79% vs 2022 (€ 6,393,656) Unfavourable step	€ 1,196,285 Revenue 2024: € 1,196,285 ▼ 10% vs 2023 (€ 1,326,048) Unfavourable step	€ 887,368 Revenue 2025: € 887,368 ▼ 26% vs 2024 (€ 1,196,285) Unfavourable step	▼ 26%
Profit after taxes	€ 271,478 Profit after taxes 2022: € 271,478 First fiscal year in the series	€ -92,709 Profit after taxes 2023: € -92,709 ▼ € 364,187 vs 2022 (€ 271,478) Unfavourable step	€ 142,934 Profit after taxes 2024: € 142,934 ▲ € 235,643 vs 2023 (€ -92,709) Favourable step	€ -130,435 Profit after taxes 2025: € -130,435 ▼ € 273,368 vs 2024 (€ 142,934) Unfavourable step	▼ € 273,368
Equity	€ 784,154 Equity 2022: € 784,154 First fiscal year in the series	€ 691,445 Equity 2023: € 691,445 ▼ 12% vs 2022 (€ 784,154) Unfavourable step	€ 834,379 Equity 2024: € 834,379 ▲ 21% vs 2023 (€ 691,445) Favourable step	€ 703,944 Equity 2025: € 703,944 ▼ 16% vs 2024 (€ 834,379) Unfavourable step	▼ 16%
Total debts	€ 2,392,897 Total debts 2022: € 2,392,897 First fiscal year in the series	€ 3,310,247 Total debts 2023: € 3,310,247 ▲ 38% vs 2022 (€ 2,392,897) Unfavourable step	€ 600,224 Total debts 2024: € 600,224 ▼ 82% vs 2023 (€ 3,310,247) Favourable step	€ 2,210,255 Total debts 2025: € 2,210,255 ▲ 268% vs 2024 (€ 600,224) Unfavourable step	▲ 268%
Cash	€ 814,537 Cash 2022: € 814,537 First fiscal year in the series	€ 756,872 Cash 2023: € 756,872 ▼ 7% vs 2022 (€ 814,537) Unfavourable step	€ 0 Cash 2024: € 0 ▼ 100% vs 2023 (€ 756,872) Unfavourable step	-
Retained profit	€ 765,604 Retained profit 2022: € 765,604 First fiscal year in the series	€ 672,895 Retained profit 2023: € 672,895 ▼ 12% vs 2022 (€ 765,604) Unfavourable step	€ 815,829 Retained profit 2024: € 815,829 ▲ 21% vs 2023 (€ 672,895) Favourable step	€ 685,394 Retained profit 2025: € 685,394 ▼ 16% vs 2024 (€ 815,829) Unfavourable step	▼ 16%
Balance sheet total	€ 3,177,051 Balance sheet total 2022: € 3,177,051 First fiscal year in the series	€ 4,001,692 Balance sheet total 2023: € 4,001,692 ▲ 26% vs 2022 (€ 3,177,051) Unchanged	€ 1,434,602 Balance sheet total 2024: € 1,434,602 ▼ 64% vs 2023 (€ 4,001,692) Unchanged	€ 2,914,199 Balance sheet total 2025: € 2,914,199 ▲ 103% vs 2024 (€ 1,434,602) Unchanged	▲ 103%
Employees (FTE)	2.6 Employees (FTE) 2022: 2.6 First fiscal year in the series	0.3 Employees (FTE) 2023: 0.3 ▼ 2.3 vs 2022 (2.6) Unchanged	0 Employees (FTE) 2024: 0 ▼ 0.3 vs 2023 (0.3) Unchanged	-

Key figures of ESTEVE PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ESTEVE PHARMACEUTICALS?

What happened at ESTEVE PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 16, 2026 New annual accounts for financial year 2025: loss of € 130,435 (▼ € 273,368 vs 2024). filed late Source: NBB ↗
2025 Jacob Tolstrup became a director. NBB
2025 Ivan Hagay became a director. NBB
Jan 27, 2014 New establishment in Machelen (Brab.). KBO
Jan 2, 2014 New establishment in Jette. KBO
Jan 2, 2014 Start of the company according to the CBE. KBO

In short

From € 271,478 profit in 2022 to € 130,435 loss in 2025.

Paid € 122,582 in corporate taxes since 2022.

Best year ever: 2022, with € 271,478 profit.

Pays suppliers within 188 days on average.

Original PDFs at the National Bank ↗

Management

Jacob Tolstrup Ivan Hagay

ESTEVE PHARMACEUTICALS

Behind ESTEVE PHARMACEUTICALS are Jacob Tolstrup and Ivan Hagay.

Directors

According to the 2025 annual accounts

Jacob Tolstrup

Director

since 2025

Ivan Hagay

Director

since 2025

Establishments

Establishment units

Physical locations of this company

Registered office

Burgemeester Etienne Demunterl. 5 box 10

1090 Jette

2.225.968.866

Pegasuslaan 5

1831 Machelen (Brab.)

Active since 27 January 2014

2.361.969.497

Burgemeester Etienne Demunterl. 5/10

1090 Jette

Active since 2 January 2014

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 68 companies are registered at this address.

All companies at this address →

BINWEY

€ 808,048 gross margin · 2025

CARROSSERIE KARREVELD

€ 2.9 million gross margin · 2024

Medtronic Belgium

€ 196.3 million revenue · 2025

LANSON REAL ESTATE

€ 12.4 million gross margin · 2025

BAMEL

€ 166,815 gross margin · 2025

+63 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0543.727.164

VAT number

BE 0543.727.164

Registered office

Burgemeester Etienne Demunterl. 5 bus 10, 1090 Jette

Names & denominations

ESTEVE PHARMACEUTICALS

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

2 January 2014

Peppol

Active · Active since 21 Nov 2025

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren

View on CBE Public ↗ Annual accounts (NBB) ↗

ESTEVE PHARMACEUTICALS

Warning lights

Financials

What happened to ESTEVE PHARMACEUTICALS?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions